Acupuncture in Myasthenia Gravis (AcuMG)

Status Completed

Clinical Trial Summary

The purpose of the study is to determine the effect acupuncture treatment on individuals with a diagnosis of Myasthenia Gravis (MG). A total of 20 people with MG will be enrolled in this study to receive acupuncture treatment 2 times a week for 12 weeks. Participants will be randomized into two groups: 1) Immediate start and 2) Delayed start (12 weeks). The delayed start group will act as a control group for the first 12 weeks, but then receive acupuncture treatment for 12 weeks. It is hypothesized that patients with MG who receive acupuncture treatment will have improved quality of life and activities of daily living compared to no treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05230082
Study type	Interventional
Source	HealthPartners Institute
Contact
Status	Completed
Phase	N/A
Start date	May 25, 2022
Completion date	April 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05039190` - Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients	Phase 3
Recruiting	`NCT04561557` - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System	Early Phase 1
Completed	`NCT01727193` - The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy	Phase 3
Completed	`NCT00285350` - Mycophenolate Mofetil in Myasthenia Gravis	Phase 3
Recruiting	`NCT05890833` - The Risk of Falls Index for Patients With Neuromuscular Disorders
Completed	`NCT05694234` - Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Not yet recruiting	`NCT05095103` - Immune Profiles in Myasthenia Gravis
Not yet recruiting	`NCT04965987` - Oxaloacetate in Myasthenia Gravis	Phase 1
Completed	`NCT02066519` - Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis	N/A
Completed	`NCT02774239` - A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)	Phase 3
Terminated	`NCT02102594` - Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)	Phase 2
Completed	`NCT02118805` - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Terminated	`NCT01828294` - Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis	Phase 1
Terminated	`NCT00727194` - Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis	Phase 2
Completed	`NCT04590716` - Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
Recruiting	`NCT04837625` - Study of Myasthenic Crisis in China
Not yet recruiting	`NCT01469858` - Perception and Multisensory Integration in Neurological Patients Using fMRI	N/A
Completed	`NCT05408702` - Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
Completed	`NCT03205306` - Myasthenia Gravis and Psyche